Linezolid molecular structure

Linezolid

Also known as: Zyvox, Zyvoxid, Linospan, Linzolid

CAS Number: 165800-03-3

Oxazolidinone antibiotic — MRSA and VRE treatment

Pharmacopeia Standards

USPEP

Mechanism of Action

First-in-class oxazolidinone; inhibits bacterial protein synthesis at an early initiation step. Binds the 23S rRNA (domain V) of the 50S ribosomal subunit, preventing formation of the 70S initiation complex (blocks fMet-tRNA binding). Unique binding site means no cross-resistance with other ribosomal inhibitors (macrolides, chloramphenicol, aminoglycosides). Bacteriostatic against staphylococci and enterococci; bactericidal against some streptococci. Weak, reversible MAO inhibitor — risk of serotonin syndrome.

Technical Specifications

Generic / INN NameLinezolid
CAS Registry Number165800-03-3
Molecular FormulaC16H20FN3O4
Molecular Weight337.35 g/mol
Typical Purity98.0–102.0%
Storage ConditionsStore below 25°C, protected from light
Shelf Life36 months from date of manufacture
CategoryOxazolidinones

Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.

Typical Applications

MRSA infections (skin/soft tissue, pneumonia, bacteremia — alternative to vancomycin), VRE infections (vancomycin-resistant Enterococcus — primary treatment), hospital-acquired pneumonia, diabetic foot infections, MDR-TB treatment protocols (BPaL and BPaLM regimens with bedaquiline + pretomanid ± moxifloxacin), difficult-to-treat bone/joint infections.

Manufacturers (2+)

View all →
Contact (Premium)

India

WHO-GMPEU-GMPCDSCO-GMP
Contact (Premium)